DK2393520T3 - Behandling af struktureret peptid - Google Patents

Behandling af struktureret peptid Download PDF

Info

Publication number
DK2393520T3
DK2393520T3 DK10704902.5T DK10704902T DK2393520T3 DK 2393520 T3 DK2393520 T3 DK 2393520T3 DK 10704902 T DK10704902 T DK 10704902T DK 2393520 T3 DK2393520 T3 DK 2393520T3
Authority
DK
Denmark
Prior art keywords
peptide
protease
phage
polypeptide
target
Prior art date
Application number
DK10704902.5T
Other languages
English (en)
Inventor
Elise Bernard
David Loakes
Marina Vaysburd
Christian Heinis
Gregory Paul Winter
Original Assignee
Bicycle Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2009/000301 external-priority patent/WO2009098450A2/en
Application filed by Bicycle Therapeutics Ltd filed Critical Bicycle Therapeutics Ltd
Application granted granted Critical
Publication of DK2393520T3 publication Critical patent/DK2393520T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Ecology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Claims (5)

1. Fremgangsmåde til fremstilling af en eller flere peptidligander, omfattende polypeptider kovalent bundet til et molekylært stillads ved to eller flere aminosyrerester, omfattende trinnene at: (a) vise en eller flere peptidligander i et genetisk displaysystem, hvor polypeptidet omfatter to eller flere reaktive grupper som danner en kovalent binding til det molekylære stillads, og mindst en sløjfe som omfatter en sekvens med to eller flere aminosyrer liggende mellem to af de reaktive grupper; (b) udsætte peptidliganderne for mere end en protease; og (c) screene peptidliganderne for binding mod et mål, og at vælge liganderne som binder til målet og er modstandsdygtige over for spaltning af den mere end ene protease.
2. Fremgangsmåde til fremstilling af en eller flere peptidligander, omfattende polypeptider kovalent bundet til et molekylært stillads ved to eller flere aminosyrerester, omfattende trinnene at: (a) vise en eller flere peptidligander i et genetisk displaysystem, hvor polypeptidet omfatter to eller flere reaktive grupper som danner en kovalent binding til det molekylære stillads, og mindst en sløjfe som omfatter en sekvens med to eller flere aminosyrer liggende mellem to af de reaktive grupper; (b) screene peptidliganderne for binding mod et mål uden en protease, og at vælge liganderne som binder til målet; (c) udsætte peptidliganderne som binder til målet for en eller flere proteaser; og (d) endvidere at screene for peptidligander som er modstandsdygtige over for protease-spaltning og binder til målet.
3. Fremgangsmåde ifølge krav 1 eller krav 2, hvor det genetiske displaysystem er fag-display.
4. Fremgangsmåde ifølge krav 1, hvor peptidliganderne som binder til målet endvidere modificeres med (a) aminosyresidekæde-modifikation eller -substitution; eller (b) polypeptidskelet-modifikation.
5. Fremgangsmåde ifølge krav 4, hvor skelet-modifikationen vælges fra gruppen bestående af at introducere, nær stedet for protease-spaltning, en D-aminosyre, en reduceret peptidbinding, og N-methylering.
DK10704902.5T 2009-02-04 2010-02-04 Behandling af struktureret peptid DK2393520T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2009/000301 WO2009098450A2 (en) 2008-02-05 2009-02-04 Methods and compositions
GBGB0913775.3A GB0913775D0 (en) 2009-08-06 2009-08-06 Multispecific peptides
PCT/EP2010/000690 WO2010089116A1 (en) 2009-02-04 2010-02-04 Structured peptide processing

Publications (1)

Publication Number Publication Date
DK2393520T3 true DK2393520T3 (da) 2015-10-26

Family

ID=41129757

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10704902.5T DK2393520T3 (da) 2009-02-04 2010-02-04 Behandling af struktureret peptid

Country Status (11)

Country Link
US (5) US8685890B2 (da)
EP (3) EP2393518B1 (da)
CN (2) CN102405060B (da)
AU (2) AU2010211283B2 (da)
CA (2) CA2751505C (da)
DK (1) DK2393520T3 (da)
ES (2) ES2896398T3 (da)
GB (1) GB0913775D0 (da)
PL (1) PL2393520T3 (da)
SG (3) SG173169A1 (da)
WO (3) WO2010089115A1 (da)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0914110D0 (en) * 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
CN103796681B (zh) 2011-06-30 2018-07-20 建新公司 T细胞活化的抑制剂
PL2764140T3 (pl) * 2011-10-07 2018-04-30 Bicyclerd Limited Modulacja specyficzności polipeptydów ustrukturyzowanych
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
WO2013172954A1 (en) 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc Peptide and peptidomimetic inhibitors
US20140274759A1 (en) 2013-03-15 2014-09-18 Bicycle Therapeutics Limited Modification of polypeptides
GB201306623D0 (en) * 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
CN105658659A (zh) * 2013-07-15 2016-06-08 北卡罗来纳州大学 蛋白酶抗性肽配体
ES2715379T3 (es) * 2013-10-28 2019-06-04 Bicyclerd Ltd Novedosos polipéptidos
CN107148425B (zh) 2014-10-29 2021-08-03 拜斯科阿迪有限公司 对mt1-mmp特异性的双环肽配体
CN105985524A (zh) * 2015-02-10 2016-10-05 北京师范大学 针对特定靶标具备指纹识别特征的多肽复合物分子的构建方法
US10385115B2 (en) 2015-03-26 2019-08-20 Duke University Fibronectin type III domain-based fusion proteins
EA037478B1 (ru) 2015-08-04 2021-04-01 Дьюк Юниверсити Генетически кодируемые внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения
US9765117B2 (en) 2015-08-24 2017-09-19 Romek Figa Peptides for treating cancer
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
GB201600903D0 (en) * 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Peptide derivaties
CA3019436A1 (en) * 2016-03-30 2017-10-05 Qualizyme Diagnostics Gmbh & Co Kg Detecting microbial infection in wounds
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
EP3467107B1 (en) * 2016-06-07 2022-06-01 Kaneka Corporation Ribosome display complex and production method therefor
WO2018053201A1 (en) * 2016-09-14 2018-03-22 Duke University Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
JP2020500150A (ja) 2016-09-23 2020-01-09 デューク ユニバーシティ 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド
EP3544621A1 (en) 2016-11-27 2019-10-02 BicycleRD Limited Methods for treating cancer
WO2018115203A1 (en) * 2016-12-23 2018-06-28 Bicyclerd Limited Peptide derivatives having novel linkage structures
US10624968B2 (en) 2017-01-06 2020-04-21 Bicyclerd Limited Compounds for treating cancer
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
TWI781145B (zh) 2017-02-28 2022-10-21 美商伊繆諾金公司 具有自分解肽連接子之類美登素衍生物及其結合物
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
GB201721265D0 (en) * 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
CN111902429A (zh) 2018-02-23 2020-11-06 拜斯科技术开发有限公司 多聚体双环肽配体
EP3774851A1 (en) * 2018-04-04 2021-02-17 BicycleTX Limited Heterotandem bicyclic peptide complexes
EP3788343B1 (en) 2018-04-30 2024-03-27 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
GB201808835D0 (en) * 2018-05-30 2018-07-11 Bicyclerd Ltd Ligands and methods of selecting binding targets for such
EP3807272A1 (en) 2018-06-13 2021-04-21 Amphista Therapeutics Ltd Bifunctional molecules for targeting rpn11
US20210283139A1 (en) 2018-06-13 2021-09-16 Amphista Therapeutics Ltd Bifunctional molecules for targeting uchl5
WO2019238886A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting usp14
GB201810325D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to PSMA
GB201810327D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
GB201810316D0 (en) * 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
IL279489B2 (en) * 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
US12594347B2 (en) 2018-09-07 2026-04-07 Duke University Nanoparticulate drug delivery systems
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
WO2020120984A1 (en) * 2018-12-13 2020-06-18 Bicycletx Limited Bicyclic peptide ligands specific for mt1-mmp
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
US12492224B2 (en) 2018-12-21 2025-12-09 Bicycletx Limited Bicyclic peptide ligands specific for PD-L1
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
WO2020225577A1 (en) 2019-05-09 2020-11-12 Bicycletx Limited Bicyclic peptide ligands specific for ox40
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
GB201914233D0 (en) 2019-10-02 2019-11-13 Bicyclerd Ltd Phage cyclisation assay
SMT202500247T1 (it) * 2019-10-03 2025-09-12 Bicycletx Ltd Complessi peptidici eterotandem biciclici
AU2021322934A1 (en) 2020-08-03 2023-03-30 Bicycletx Limited Peptide-based linkers
WO2024151615A1 (en) * 2023-01-10 2024-07-18 The University Of North Carolina At Chapel Hill Mrna display libraries and methods of use
WO2025046244A1 (en) * 2023-09-01 2025-03-06 Bicycletx Limited Tlr3 binding bicyclic peptide ligands
DE102023133734A1 (de) * 2023-12-01 2025-06-05 Technische Universität Darmstadt, Körperschaft des öffentlichen Rechts Schnelle Bestimmung von Analytgehalten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780279A (en) * 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
US20030166003A1 (en) * 1999-06-14 2003-09-04 Cochran Andrea G. Structured peptide scaffold for displaying turn libraries on phage
EP1452868A2 (en) * 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
WO2006078161A1 (en) * 2005-01-24 2006-07-27 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
GB2428293A (en) * 2005-07-13 2007-01-24 Domantis Ltd Phage display libraries
EP2653545A1 (en) * 2008-02-05 2013-10-23 Bicycle Therapeutics Limited Methods and compositions

Also Published As

Publication number Publication date
US8685890B2 (en) 2014-04-01
CA2751505A1 (en) 2010-08-12
CN102405060A (zh) 2012-04-04
US20160046928A1 (en) 2016-02-18
EP2393520A1 (en) 2011-12-14
AU2010211283B2 (en) 2015-12-10
SG173460A1 (en) 2011-09-29
CN102405059A (zh) 2012-04-04
CA2750969C (en) 2019-05-07
PL2393520T3 (pl) 2016-01-29
US20120101256A1 (en) 2012-04-26
WO2010089115A8 (en) 2011-12-22
CA2750969A1 (en) 2010-08-12
AU2010211282A1 (en) 2011-08-18
WO2010089116A1 (en) 2010-08-12
US8778844B2 (en) 2014-07-15
GB0913775D0 (en) 2009-09-16
EP2393519B1 (en) 2018-01-03
US20120142541A1 (en) 2012-06-07
EP2393518A1 (en) 2011-12-14
SG173169A1 (en) 2011-09-29
EP2393520B1 (en) 2015-07-15
ES2551580T3 (es) 2015-11-20
US20120101253A1 (en) 2012-04-26
US9644201B2 (en) 2017-05-09
EP2393519A1 (en) 2011-12-14
ES2896398T3 (es) 2022-02-24
AU2010211282B2 (en) 2016-02-11
US9670482B2 (en) 2017-06-06
SG10201503705UA (en) 2015-06-29
EP2393518B1 (en) 2021-08-04
CN102405060B (zh) 2016-04-13
WO2010089117A1 (en) 2010-08-12
WO2010089115A1 (en) 2010-08-12
CN102405059B (zh) 2016-10-12
US20140163201A1 (en) 2014-06-12
CA2751505C (en) 2019-08-20
AU2010211283A1 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
DK2393520T3 (da) Behandling af struktureret peptid
DK2464727T3 (da) Peptidbiblioteker
JP2013518807A (ja) 多重特異性ペプチド
JP2013518558A (ja) 構造化されたペプチドプロセシング